Baidu
map

New Engl J Med :乳腺癌患者福音:卡培他滨对于棘手的乳腺癌效果神奇!

2017-06-04 Heather_z727 来宝网

一项临床实验发现,一种名为卡培他滨的药物可以延长乳腺癌晚期患者的寿命,尤其是对标准治疗已经不起作用的患者。肿瘤学家称这叫做“治疗进展。”

【卡培他滨:延长晚期乳腺癌患者生存期】一项临床实验发现,一种名为卡培他滨的药物可以延长乳腺癌晚期患者的寿命,尤其是对标准治疗已经不起作用的患者。肿瘤学家称这叫做“治疗进展。”

研究人员表示:“卡培他滨是FDA批准使用的抗癌药,我们一直使用它来治疗癌症。卡培他滨是药片形式的,它比常规化疗的毒性小很多。最重要的是,它可以延长乳腺癌患者的总生存期。”

早在1998年,卡培他滨已经获批用来治疗扩散到其他器官的晚期乳腺癌。在日本和韩国也在进行其针对不同患癌女性的不同作用。此次试验的参与者为910名乳腺癌患者,她们同时缺少一种HER2的蛋白质,这就意味着常规乳腺癌药物,如赫赛汀对她们不起任何作用。这些患者病情发展的速度非常之快,但是在使用卡培他滨治疗额过程中,患者复发或死亡的风险降低30%,五年生存率达到74%。

研究人员表示:“我们知道,这个世界上没有万灵药,但是卡培他滨确实可以在一定程度上延长晚期乳腺癌患者的生命,此次试验也证明了进展治疗的意义所在。”

此次研究也证明了对一种抗癌药物没有反应的患者,不一定对其他药物没有反应,我们在卡培他滨上看到的治疗棘手乳腺癌得新希望。”此次研究的完整报告发表于《新英格兰医学杂志》上。

原始出处

Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017; 376:2147-2159June 1, 2017DOI: 10.1056/NEJMoa1612645.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1785457, encodeId=ea441e85457e6, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Jul 26 11:56:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081363, encodeId=f57520813635b, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 11 14:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293504, encodeId=a89512935044e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571037, encodeId=049015e103741, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607614, encodeId=e2d6160e61466, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
    2017-07-26 haouestc
  2. [GetPortalCommentsPageByObjectIdResponse(id=1785457, encodeId=ea441e85457e6, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Jul 26 11:56:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081363, encodeId=f57520813635b, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 11 14:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293504, encodeId=a89512935044e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571037, encodeId=049015e103741, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607614, encodeId=e2d6160e61466, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
    2018-03-11 spoonycyy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1785457, encodeId=ea441e85457e6, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Jul 26 11:56:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081363, encodeId=f57520813635b, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 11 14:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293504, encodeId=a89512935044e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571037, encodeId=049015e103741, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607614, encodeId=e2d6160e61466, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1785457, encodeId=ea441e85457e6, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Jul 26 11:56:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081363, encodeId=f57520813635b, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 11 14:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293504, encodeId=a89512935044e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571037, encodeId=049015e103741, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607614, encodeId=e2d6160e61466, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1785457, encodeId=ea441e85457e6, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed Jul 26 11:56:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081363, encodeId=f57520813635b, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Mar 11 14:56:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1293504, encodeId=a89512935044e, content=<a href='/topic/show?id=a82f36493c4' target=_blank style='color:#2F92EE;'>#卡培他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36493, encryptionId=a82f36493c4, topicName=卡培他滨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571037, encodeId=049015e103741, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607614, encodeId=e2d6160e61466, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 05 23:56:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]

相关资讯

Adv Sci:低剂量双酚A潜在乳腺致癌作用的研究进展

激素水平被认为是促进乳腺癌发生的关键因素。环境内分泌干扰物(EDCs)是一类可干扰内源性激素正常功能的人工化合物。人们接触环境内分泌干扰物机会的大幅度增加被认为是导致乳腺癌发病率不断攀高的重要诱因之一。双酚A(bisphenol a, BPA)是目前产量最大、应用最广泛、研究最彻底的环境内分泌干扰物之一。动物实验和细胞实验的研究结果表明,双酚A暴露可以促进乳腺癌的发生与发展。然而,这些研究重点关注

美国癌症研究所:每日10 g酒精,也增乳腺癌风险

“每日即便饮一小杯酒精含量约10 g的各种酒,即使是啤酒,也会增加绝经期前女性5%的乳腺癌风险,和9%的绝经期后女性罹患风险。”近期一项来自美国癌症研究所(AICR)和世界癌症研究基金(WCRF)的报告称。

盘点:近期乳腺癌研究精华汇总

乳腺癌是女性最常见的恶性肿瘤之一,目前我国乳腺癌发病率不断攀升,乳腺癌的机制及治疗一直是科学家们研究的热门,小编为大家盘点了近期乳腺癌治疗及机制方面的一些重要研究进展与大家分享。

World Cancer Research Fund:每天半杯酒也会增加乳腺癌风险!

近日,世界癌症研究基金会作了一个关于饮酒和乳腺癌风险的报告:每天喝半杯酒或喝一小杯啤酒会增加患乳腺癌的风险。同时,他们也支持关于定期强化锻炼能够降低乳腺癌发病风险的研究。

Small:ATP/pH双响应纳米粒用于乳腺癌的靶向治疗

两亲性嵌段聚合物通过疏水作用的自组装能够形成纳米结构,可用于纳米载药体系的构建。然而,实现自组装所需的亲疏水嵌段比例要求限制了载药体系疏水核心的载药容量。复旦大学蒋晨教授团队基于抗肿瘤药物阿霉素蒽醌结构与双链DNA结构的嵌插作用,发现可通过ATP 敏感适配体与阿霉素键合材料的嵌插与疏水双重作用形成纳米粒。以酸敏感的希夫碱键将阿霉素与生物相容性聚氨基酸骨架进行共价连接,再与适配体复合,可同时满足提高

胸大、胸小哪个更容易得乳腺癌?

现实生活中很多男生喜欢大胸妹子,而很多女生则认为“胸大有什么好的?胸大更容易的乳腺癌。”这一说法是真的吗?

Baidu
map
Baidu
map
Baidu
map